Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Hookipa Pharma ( (HOOK) ) is now available.
On May 21, 2025, Hookipa Pharma and its subsidiary entered into an Asset Purchase Agreement with Gilead Sciences to sell assets related to their HB-400 and HB-500 programs. The agreement includes a purchase price of up to $10 million, with $3 million payable at closing and the remainder contingent on a three-phase transfer plan. The transaction requires stockholder approval and involves customary conditions and indemnifications. Additionally, the collaboration agreement with Gilead will terminate upon closing, and the ongoing HB-500 trial will be wound down.
The most recent analyst rating on (HOOK) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Hookipa Pharma stock, see the HOOK Stock Forecast page.
Spark’s Take on HOOK Stock
According to Spark, TipRanks’ AI Analyst, HOOK is a Underperform.
Hookipa Pharma’s overall stock score is low, primarily due to its poor financial performance, including zero revenue and ongoing losses. The technical analysis provides some short-term optimism, but the long-term trends remain negative. Valuation metrics further highlight the company’s financial struggles. Without any corporate events or earnings call data, the focus remains on financial challenges that require strategic intervention for improvement.
To see Spark’s full report on HOOK stock, click here.
More about Hookipa Pharma
Hookipa Pharma is a biotechnology company focused on developing novel immunotherapies for infectious diseases and cancers. The company is primarily engaged in clinical development programs targeting hepatitis B virus (HB-400) and human immunodeficiency virus (HB-500).
Average Trading Volume: 86,705
Technical Sentiment Signal: Sell
Current Market Cap: $21.27M
See more insights into HOOK stock on TipRanks’ Stock Analysis page.